648.05
+2.26%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Solara Active Pharma Sciences
Its shares trade on NSE under the ticker SOLARA.NS. It has been listed since 27 June 2018. In the fiscal year to 31 March 2026, it reported revenue of ₹13.69bn and a net loss of ₹74.1m. At that date it held total assets of ₹23.33bn and shareholders' equity of ₹12.53bn.
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The firm works with pharmaceutical companies from North America, Europe, and Japan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jun 2018
- Employees
- 2,361
- Website
- solara.co.in ↗
Leadership
Pay as last reported
- Mr. Ramakrishnan RajagopalNon-Executive Independent Chairman of the Board₹1.0m
- Mr. Sandeep RaoChief Executive Officer, Managing Director, Executive Director, since 2025₹5.3m
- Mr. Sarat KumarChief Financial Officer
- Mr. Mohan MuthunarayananChief Operating Officer, Whole Time Director, since 2024
- Ms. Pooja KumarCompliance Officer, Company Secretary
- Mr. Mohanraj S.Additional Whole Time Director, since 2025
- Mr. V. Sundara MoorthyChief Quality Officer
- Mr. Manish GuptaNon-Executive Director₹300,000
- Mr. Arun PillaiNon-Executive Director
- Mr. Rajiv NabarNon-Executive Independent Director₹1.0m
- Dr. Kausalya SanthanamNon-Executive Independent Director₹1.0m
- Mr. Rajendra SrivastavaNon-Executive Independent Director₹1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Solara Active Pharma Sciences Ltd manufactures Albendazole and Aprepitant for global markets.
- The company employs 2,361 full-time staff in its Chennai headquarters.
- Commercial products include Artesunate and Brivaracetam for various therapeutic segments.
Weaknesses
- The firm operates solely through the single API business segment.
- Listed on the stock market on 27 June 2018 only.
- Headquarters located in Chennai, Tamil Nadu, limits local diversity.
Opportunities
- Expanding sales of Mirabegron to treat overactive bladder conditions.
- Growing demand for Ibuprofen Sodium Dihydrate as an anti-inflammatory agent.
- Developing new formulations for Pentoxifylline and other cardiovascular agents.
Threats
- Intense competition from other pharmaceutical companies in North America.
- Regulatory challenges in Europe affecting API manufacturing standards.
- Market volatility in Japan impacting export revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.